The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Mayo Clinic
Merck Sharp & Dohme LLC
Tizona Therapeutics, Inc
Essen Biotech
Wake Forest University Health Sciences
Transgene
Hummingbird Bioscience
Memorial Sloan Kettering Cancer Center
NuCana plc
Medicenna Therapeutics, Inc.
Providence Health & Services
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc
Pliant Therapeutics, Inc.
Eli Lilly and Company
Queen Mary University of London
OHSU Knight Cancer Institute
OncoSec Medical Incorporated
Rutgers, The State University of New Jersey
Centre Leon Berard
Odonate Therapeutics, Inc.
Incyte Corporation
ETOP IBCSG Partners Foundation